No increase in relapse was observed in the 3 months after IVF.
Assisted reproduction technology has previously been associated with increased risk of disease activity in women with multiple sclerosis (MS; NEJM JW Neurol Mar 2013 and Ann Neurol 2012; 72:682). In vitro fertilization (IVF) includes ovarian stimulants and other hormones that are thought to impact inflammatory activity.
In the present retrospective study, investigators assessed relapse rates in 225 women with MS who underwent a total of 338 IVF procedures in France from 2010 to 2015. Most women received gonadotropin-releasing hormone (GnRH) antagonists. Overall, 142 pregnancies (109 from IVF) occurred in 121 different women. The annualized relapse rate (ARR) was 0.35 in the year before IVF, 0.20 in the 3 months before IVF, and 0.18 in the 3 …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)